New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.
about
Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectivesTissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer PhenotypesTargeting TBP-Associated Factors in Ovarian CancerUpdate on immune checkpoint inhibitors in gynecological cancersPotential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply.FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsBioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line.Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian CarcinomaCoexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.Lipid starvation and hypoxia synergistically activate ICAM1 and multiple genes in an Sp1-dependent manner to promote the growth of ovarian cancerProteomics in cancer biomarkers discovery: challenges and applications.Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.Functional redundancy of the Notch pathway in ovarian cancer cell lines.Does the Presence of Endometriosis Affect Prognosis of Ovarian Cancer?The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.Molecular pathogenesis of ovarian clear cell carcinoma.An overview of early investigational therapies for chemoresistant ovarian cancer.Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?Current and emerging treatment options in the management of advanced ovarian cancer.Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer.Structural and calorimetric studies demonstrate that the hepatocyte nuclear factor 1β (HNF1β) transcription factor is imported into the nucleus via a monopartite NLS sequence.GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.Does one size fit all? The updated ovarian cancer staging: Still a work in progress.Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.Expression and function of nuclear receptor coactivator 4 isoforms in transformed endometriotic and malignant ovarian cells.Long-term survival of patients with mismatch repair protein-deficient, high-stage ovarian clear cell carcinoma.The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.DNA damage repair in ovarian cancer: unlocking the heterogeneity.Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer
P2860
Q26775315-6B34FD6D-A002-4B73-A310-47971B0C60EEQ26781924-7DFCDFC8-BE4F-4FF7-A70E-ADF2A4BE9933Q26866045-8BA762CC-7A0D-48E5-8DE1-35A0569E9363Q28076497-629D2D8E-623B-4CF6-88F8-CD003626E955Q33624680-A7161430-3A89-48D8-B9FA-F4D6C1B0041FQ33651605-107C7DC2-2D96-46C2-843D-857C9A3AB81DQ33655175-4126412E-E60C-4380-B9EB-03A7E43C2766Q33746474-A44AB9E5-B80C-49AE-81D4-A8BDEF43AF92Q35020913-4ED1E318-88A1-4E5D-9D53-603115EC77E1Q35413390-20414F53-2802-4A4A-AD6F-61C88EB04092Q35592114-D244171E-0191-4942-8460-5E2C700C4CF1Q36199823-05E75DAD-FFBC-4D6C-AF46-0B820CDDCB8BQ36826591-6F98F17D-B083-4DC4-9DEB-490798F09669Q37225222-3CDB1317-52FE-46C4-8873-AB8A0C4BC8BAQ37289384-F98EF809-89D3-4EE9-AD83-B1279802E16BQ37625908-C7AD8D1B-5B51-4D72-A3C2-040A75320068Q38175044-E3959F3D-3AB2-449A-B6F0-6EA69D2FA292Q38465850-ACEC3B05-C3AD-46CD-BA13-4C4541F27EF3Q38553247-9A0807E9-5854-4257-BE5F-B76DD869468DQ38669765-AD7FF0C9-346F-482D-B4C9-62D6D676771DQ38693040-37713E66-843E-4FD5-A19D-99B1107AC6B6Q38751236-665F79C7-97A3-402C-A462-D82D22710B28Q38884686-869CC516-C91F-4B52-9019-CE8DFDB2B5A7Q38889364-2E204BEB-C00A-455B-B51D-C28259A43136Q39130754-84CDAEAC-422D-48DE-BE52-6D0A8D3D6EB5Q41517113-6FFABB08-773F-4778-831A-D1746426AD5FQ42335706-98607D61-9713-49CA-8483-4A1BC1C3D018Q45015440-403F4AA8-CF72-4F22-B698-2365807DD822Q48227188-7B98EB93-D09E-443C-8D01-31B10907651DQ50052852-9B70A9CD-3815-4274-8320-31AB2EE9D88AQ51626586-48691071-4485-487C-82C8-0BEE589C2C48Q53529807-9D2CD9CA-00B6-4F2E-B5CC-0885EEAED419Q55399645-2316CE55-B1C5-4E3A-AD1F-0F2D6410302CQ58613115-9A4B7029-CF2B-4C9B-A4CA-8EA37044AB90
P2860
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.
@en
type
label
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.
@en
prefLabel
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.
@en
P2860
P921
P356
P1476
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2013.126
P407
P50
P5008
P577
2013-04-04T00:00:00Z